AugMedics News
15 articles
Augmedics snaps up $82.5M advance spinal surgery navigation using AR and AI
Augmedics, a startup that has developed an augmented reality-based navigation platform for spinal surgeries, has raised $82.5 million in a Series D funding round. The round was led by CPMG and included participation from Evidity Health Capital, H.I.G. Capital, Revival Healthcare Capital, and Almeda Ventures. The funding will be used to expand the platform and for commercial development. The companys xvision technology has been used in over 4,000 procedures since its approval by the FDA in 2019. The company plans to remain focused on spinal surgeries but sees potential for expansion into other areas in the future.
InvestmentExpand
Augmedics Launches New Features, New Indications in Expansion of xvision Augmented Reality Platform
Augmedics to bring AR spine surgery to Veterans Health Administration
Augmedics has been awarded a Federal Supply Schedule contract by the U.S. Department of Veteran Affairs. This contract allows the Veterans Health Administration to access Augmedics Xvision system, an augmented reality spine system that improves precision in pedicle screw placement. The contract is expected to bring growth-positive impact to Augmedics. The companys President and CEO, Kevin Hykes, expressed their honor in bringing this technology to the VA and revolutionizing spine surgery for veterans and surgeons. The VA is the largest healthcare system in the U.S. and operates at 1,298 facilities.
Customers
Augmented Reality Pioneer Augmedics Adds Former DePuy Synthes President to Board of Directors
Augmented Reality Pioneer Augmedics Announces New Board Leadership
Augmedics raises $36 million led by Almeda Ventures for AR x-ray vision
Israeli medical device company Augmedics has raised $36 million in a funding round led by Almeda Ventures. The round was initially planned to raise $25 million but grew due to excess demand. The funds will be used to develop the next generation of the companys augmented reality system and expand marketing operations. Augmedics xvision system allows surgeons to view CT scans of patients in real-time during surgery, providing a 3D augmented image of the patients anatomy. The system has received FDA approval and has been used in 250 spinal cord surgeries. The investment round brings the total capital raised by Augmedics to $63 million.
InvestmentExpand
Augmedics Employees Lead $15 Million Series B Financing to Secure and Successfully Launch Company Amid COVID-19 Crisis
First Augmented Reality Spine Surgery Using FDA-Cleared Augmedics xvision™ Spine System Completed in U.S. - Ortho Spine News
Augmedics xvision Spine System, an augmented reality guidance system for surgery, has been successfully used for the first time in a spinal fusion surgery in the United States. The system allows surgeons to visualize the 3D spinal anatomy of a patient during surgery and accurately navigate instruments and implants. The surgery was performed by Johns Hopkins University surgeons. The xvision Spine System aims to improve accuracy, safety, operating efficiencies, and patient outcomes in spinal procedures. It addresses the unmet needs of surgeons by providing better control and visualization. Augmedics plans to explore additional surgical applications for the xvision system beyond spinal surgery.
Customers
Augmedics Announces FDA 510K Clearance and U.S. Launch of xvision™, the First Augmented Reality Guidance System for Surgery
These Goggles Enable Surgeons to See Right Through You
Israel-based Augmedics has developed an augmented reality headset called xvision that allows surgeons to visualize patients in real time, seeing through their skin, muscle tissue, and bone. The headset is currently being used in clinical trials for minimally invasive spine surgeries in Israel. Augmedics plans to sell the xvision headset to hospitals at cheaper prices than conventional surgical navigation systems. The company has raised $8.3 million in funding to date and employs 20 people. The headset has been used in six surgeries so far.
CustomersInvestment
Augmedics Begins Spine Navigation System Human Trial
Augmedics, an Israeli company, has started a clinical trial of its xvision-spine augmented-reality surgical navigation system. The trial aims to evaluate the safety, performance, accuracy, and usability of the system during spine fusion procedures. The company expects to enroll between 8 and 22 subjects and plans to place a minimum of 85 screws using the xvision-spine system. The trial will assess the accuracy of pedicle screw placement and evaluate the systems usability through a User Experience Questionnaire. Augmedics plans to have dozens of systems installed in U.S. hospitals within a year and is seeking strategic partnerships for global distribution.
CustomersPartnersInvestmentExpand
Augmedics Begins First-in-Human Clinical Trial of xvision-spine (XVS) Augmented-Reality Surgical Navigation System
Augmedics Study: Positive Results for xvision Spine System
Augmedics, an Israeli company, has completed its second cadaver study using its augmented-reality (AR) surgical navigation system, xvision-spine system (XVS). The study involved surgeons from Johns Hopkins Hospital and two hospitals in Israel, who placed 120 pedicle screws in five separate cadavers with a screw placement accuracy of 96.7%. The XVS allows surgeons to see and navigate inside a patient’s body during complex procedures. The company partnered with neurosurgeons from Johns Hopkins Hospital for this study.
Partners
Augmedics Successfully Completes Cadaver Study with Johns Hopkins Hospital Surgeons Using xvision-spine (XVS) Augmented-Reality Surgical Navigation System
Augmedics Secures $8.3 Million in Series A Funding for Augmented-Reality Surgical Visualization System
Augmedics, an Israeli developer of an augmented-reality (AR) surgical visualisation system, has raised $8.3m in a series A funding round. The round was led by AO Invest, and included participation from the Israeli Innovation Authority, Terra Venture Partners and other undisclosed investors. The funding will be used to complete R&D, as well as pre-clinical and clinical trials of its ViZOR System. The company will also establish strategic distribution partnerships and seek 510(k) clearance for the ViZOR from the US Food and Drug Administration.
Investment
